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3) The major risk factor for glaucoma is elevated intraocular pressure (IOP), which leads to apoptosis and loss of retinal ganglion cells. 4) In treating glaucoma, the focus is on reducing IOP, and retinal and optic nerve damage. However, the retinal and optic nerve damage that result from elevated IOP are not satisfactorily controlled by the current therapies. Therefore, the search for successful therapies for glaucoma is a high priority.
Nitric oxide (NO) is synthesized from the guanidino-nitrogen of L-arginine and molecular oxygen by nitric oxide synthase (NOS). Endothelial NOS and neuronal NOS are present in most ocular tissues, including those responsible for aqueous dynamics, i.e. the ciliary processes, ciliary muscle and trabecular meshwork. [5] [6] [7] NO causes relaxation of the ciliary muscle and trabecular meshwork. 8, 9) The relaxation of the ciliary muscle tends to decrease trabecular outflow facility and increase uveoscleral outflow, while relaxation of the trabecular meshwork increases trabecular outflow facility. Thus the effects of NO on IOP vary depending upon the site of action. On the other hand, recently, Kiel et al. 10) reported that the systemic inhibition of NOS by N G -nitro-L-arginine methyl ester (L-NAME) causes a large, rapid decrease in IOP by due to ciliary vasoconstriction in rabbits. Therefore, agents that inhibit NOS in the blood vessel of ciliary body might prove useful in the treatment of glaucoma.
Diethyldithiocarbamate (DDC) is a potent NOS inhibitor and radical scavenger. 11, 12) However, DDC is unstable in neutral solution, and is not able to penetrate through the cornea into the aqueous humor. 13) Disulfiram (DSF), a dimer of DDC, has long been used to treat alcoholic syndrome without severe side effects. 14) However, its application in the ophthalmic field is limited due to its poor water solubility.
Cyclodextrins are cyclic oligosaccharides comprising R-Dglucose linked by R-(1-4) glucosidic bonds. Natural cyclodextrins and their synthetic derivatives have been studied extensively to improve certain properties such as their solubility, stability, and/or bioavailability.
15) 2-Hydroxypropyl-bcyclodextrin (HPbCD) is a cyclic oligosaccharide with a hydrophilic outer surface and a lipophilic cavity that is capable of forming inclusion complexes with many lipophilic drugs by taking up the drug molecule, or part of it, into its lipophilic cavity. 16, 17) In aqueous solution, hydroxypropylmethylcellulose (HPMC), a water-soluble polymer, increases the solubilizing effect of cyclodextrins on lipophilic drugs by increasing the stability constants of the drug/cyclodextrin inclusions. 18) We previously found that HPbCD and HPMC increase the solubility of DSF, and solve the problem of its poor water solubility. 19) In this study, we investigated the effect of DSF solutions containing HPbCD and HPMC (DSF eye drops) on IOP in rabbits.
MATERIALS AND METHODS

Animals
Male Japanese albino rabbits, 2.5-3.0 kg, were used in this study. They were housed under standard conditions (12 h/d fluorescent light (07:00-19:00), 25°C room temperature) and allowed free access to a commercial diet (CR-3, Clea Japan Inc., Tokyo) and water. All procedures were performed in accordance with the Kinki University Faculty of Pharmacy Committee Guidelines for the Care and Use of Laboratory Animals and the Association for Research in Vision and Ophthalmology resolution on the use of animals in research.
Reagents DSF was kindly donated by Ouchi Shinko Chemical Industrial Co., Ltd. (Tokyo, Japan). HPbCD (average molar substitution, 0.6; average MW, 1380) was purchased from Nihon Shokuhin Kako Co., Ltd. (Tokyo, Japan). HPMC was provided by Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). Benzalkonium chloride was obtained from Kanto Chemical Co., Inc. (Tokyo, Japan), and 0.4% Benoxil was provided by Santen Pharmaceutical Co., Ltd. (Osaka, Japan). All other chemicals used were of the highest purity commercially available.
Preparation of Eye Drops Containing DSF Included with HPbCD HPbCD was added to saline containing 0.005% benzalkonium chloride along with DSF fine powder, and then the HPMC was added to the solution. The mixture was stirred for 24 h in the dark at room temperature and filtered through a Minisart CE (pore size of 0.20 mm, Costar, Cambridge, MA, U.S.A.). The adsorption of DSF was not observed by filtration. The compositions of the DSF eye drops are shown in Table 1 .
In Vitro Transcorneal Penetration of DDC from DSF Eye Drops The in vitro transcorneal penetration of DDC from DSF eye drops was examined using the method of Iwata et al. 20) Adult Japanese albino rabbits weighing 2.5 to 3.0 kg were killed by injecting a lethal dose of pentobarbital into the marginal ear vein. The eyes were removed and the corneas were carefully separated from other ocular tissues. The individual corneas were placed on a methacrylate cell designed for transcorneal penetration studies. The side of the chamber (donor chamber) exposed to the exterior surface of the cornea was filled with 0.1 or 0.25% DSF eye drops. The other side of the chamber (reservoir chamber) was filled with 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) buffer (pH 7.4) containing 136.2 mM NaCl, 5.3 mM KCl, 1.0 mM K 2 HPO 4 , 1.7 mM CaCl 2 and 5.5 mM glucose. The experiments were performed at 35°C for 6 h. Fifty microliters of sample solution was withdrawn from the reservoir chamber at the indicated time intervals and replaced with the same volume of buffer. DSF and DDC concentrations in the samples were determined by the following HPLC method. Fifty microliters of filtrate was added to 100 ml methanol containing 0.25 mg indomethacin (internal standard), and the mixture solution were filtered through a Chromatodisk 4A (pore size 0.45 mm, Kurabo Industries Ltd., Osaka, Japan). The solution (10 ml) was injected into a Mightysil RP-18 (3 mm, column size: 2.0 mmϫ50 mm) column (Kanto Chemical Co., Inc., Tokyo, Japan) using a Shimadzu LC-10AD system equipped with a column oven CTO-6A (Shimadzu Corp., Kyoto, Japan). The mobile phase consisted of 45% acetonitrile containing 0.1% trifluoroacetic acid at a flow rate of 0.25 ml/min, the column temperature was 35°C, and the wavelength for detection was 215 nm. 21) Corneal viability was monitored by measuring thickness (0.0625 cm, average for 5 rabbits, no significant changes in thickness was observed over the 6 h period).
In Vivo Transcorneal Penetration of DDC from DSF Eye Drops The in vivo transcorneal penetration of DDC from DSF eye drops was determined as described by Meisner et al. 22) Adult Japanese albino rabbits weighing 2.5 to 3.0 kg were anesthetized by injecting pentobarbital (0.6 mg/kg) through the marginal ear vein, and a topical anesthetic (0.4% Benoxil) was instilled into each eye 3 min before sampling of the aqueous humor. Then, a 29 gauge injection needle connected to silicon tubing (inner diameter: 0.5 mm, Fuji Systems Co., Tokyo, Japan) joined to a 25 ml microsyringe (Ito Corp., Tokyo, Japan) was inserted into the eye to obtain aqueous humor samples, and 50 ml of 0.1, 0.25 or 0.5% DSF eye drops was instilled into the eyes of the rabbits. The aqueous humor samples (5 ml each) were removed from the anterior chamber of the eye for 0-90 min. The DSF and DDC concentrations were determined by HPLC as described above.
The DDC concentration data in the aqueous humor after a single injection of 20 ml of DDC solution into the anterior chamber of the eye were analyzed according to Eq. 1 23) : (1) where C AH is the DDC concentration in the aqueous humor at time t, C 0 is the initial concentration of DDC in the aqueous humor, and k e is the elimination rate constant of DDC from the aqueous humor. The k e obtained in 5 experiments was 0.0502/min.
The DDC concentration data in the aqueous humor after the instillation of 50 ml of DSF eye drops were analyzed according to Eq. 2: (2) where C AH is the DDC concentration in the aqueous humor, X is the dose of the DSF eye drop instillation, k a is the absorption rate constant, V d is the distribution volume (anterior chamber, ca. 150 ml), F is the fraction of DDC absorption, and t is the lag time.
23) The area under the DDC concentration-time curve (AUC DDC ) was calculated according to the following equation (Eq. 3): (3) Briefly, AUC was determined according to the trapezoidal rule up to the last DDC concentration measurement point.
Measurement of Intraocular Pressure in Rabbits
The experiment was carried out according to Bonomi et al. 24) The IOP in rabbits was measured with an electronic tonometer (Medtronic SOLAN, Jacksonville, FL, U.S.A.) under surface anesthesia (0.4% Benoxil). IOP elevation was induced by the rapid infusion of 5% glucose solution through the rabbit marginal ear vein. The amounts injected were 15 ml/kg of body weight and the infusion was accomplished in all animals within 20 s. The various eye drops were instilled 30 min prior to the infusion of the 5% glucose solution. The area under the curve (AUC IOP ) of the IOP (mmHg) versus time (min) (the area under IOP-time curve) was calculated as the difference of AUC in rabbits with or without the infusion of 5% Measurement of NO Levels in the Aqueous Humor Adult Japanese albino rabbits weighing 2.5 to 3.0 kg were anesthetized by injecting pentobarbital (0.6 mg/kg) through the marginal ear vein, and a topical anesthetic (0.4% Benoxil) was instilled into each eye 3 min before sampling of the aqueous humor. Then, a 29 gauge injection needle connected with silicon tubing (inner diameter: 0.5 mm, Fuji Systems Co., Tokyo, Japan) joined to a 25 ml microsyringe (Ito Corp., Tokyo, Japan) was inserted into the eye to obtain aqueous humor samples, and 50 ml of DSF eye drops was instilled into the eyes. Aqueous humor samples (5 ml each) were collected from the anterior chamber of the eye, and the NO levels in the aqueous humor were measured using a Hitachi F-3000 Fluorescence Spectrophotometer (Hitachi, Tokyo, Japan) and NO 2 /NO 3 Assay Kit-F II (Wako, Osaka, Japan) according to the manufacturer's instructions. In this paper, NO amounts reflect the levels of the NO 2 Ϫ and NO 3 Ϫ metabolites, which are the products of NO. Statistical Analysis All values are presented as meanϮstandard error of the mean (S.E.). Unpaired Student's or Aspin-Welch's t-tests were used to evaluate statistical differences, and multiple groups were evaluated by one-way analysis of variance followed by Dunnett's multiple comparison. p values less than 0.05 were considered significant. Figure 1 shows in vitro transcorneal penetration of DDC from DSF eye drops using rabbit corneas. In this study, only DDC, not DSF, was detected. The amount of penetrated DDC increased after instillation of 0.1 or 0.25% DSF eye drops. There were no significant differences in the amount of penetration between the two DSF eye drop formulations. Figure 2 shows the DDC concentrations in the aqueous humor after the instillation of 0.1 or 0.25% DSF eye drops into rabbit eyes, and Table 2 summarizes the pharmacokinetic parameters calculated from the in vivo transcorneal penetration data. In the aqueous humor, only DDC was detected, with a peak concentration observed at 20 min after the instillation of 0.25% DSF eye drops. In contrast to the in vitro transcorneal penetration results, the amount of DDC penetration for the 0.25% DSF eye drops was higher than that for the 0.1% eye drops, and the values of AUC DDC and k a for the 0.25% DSF eye drops were approximately 2.5-fold higher in comparison with those of the 0.1% DSF eye drops. Figure AUC DDC , the area under the DDC concentration-time curve; k a , absorption rate constant; t, lag time. The data are presented as meansϮS.E. of 5 independent rabbits. * pϽ0.05, vs. 0.1% DSF eye drops.
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Fig. 3. Effect of DSF Eye Drops on IOP in Rabbits Receiving a Rapid Infusion of 5% Glucose Solution
Rabbits receiving a rapid infusion of 5% glucose solution were instilled with 50 ml of saline or DSF eye drops. Saline instilled rabbits (᭺), 0.1% DSF eye drop instilled rabbits (᭹), 0.25% DSF eye drop instilled rabbits (᭡), 0.5% DSF eye drop instilled rabbits (). The data represent as meansϮS.E. of 5 independent rabbits. and Table 3 shows the IOP-reducing effect of DSF eye drops. The elevation of IOP in rabbits was induced by the rapid infusion of 5% glucose solution (15 ml/kg) through the marginal ear vein. The IOP was highest 10 min after the infusion, and returned to the pre-infusion level by 50 min after the infusion. Rabbits instilled with DSF eye drops showed a significantly reduced level of IOP elevation compared with rabbits instilled with saline, and the IOP-reducing effect increased with the increase in the DSF concentration of the eye drops (Table 3 ). Figure 4 shows the changes of NO levels in the aqueous humor of rabbits instilled with saline or 0.5% DSF eye drops. NO levels in the aqueous humor of rabbits rose following the rapid infusion of 5% glucose solution into the marginal ear vein, and reached a maximum at 20 min. The instillation of DSF eye drops also reduced the degree of NO elevation in the aqueous humor.
DISCUSSION
Glaucoma is a major cause of blindness, with an estimated 70 million people affected worldwide. Over the course of their lives, 10% of these patients will become bilaterally blind.
3) However, for reasons of effectiveness and safety, a potent anti-glaucoma drug for human use has not yet been introduced. From the view point of the recent steep increase in the number of patients with glaucoma in modern aging societies, the development of effective and safe anti-glaucoma drugs is highly anticipated. In this study, we investigated the effects of DSF eye drops on IOP.
The safety of eye drops is an important factor. It has been reported that HPbCD ranks second in safety to g-CD in a variety of CD derivatives used for eye drop applications. 25) Moreover, Jansen et al. 26) reported no irritation to eye membranes by HPbCD solutions less than 12.5%. Therefore, we used 1-5% HPbCD, which is low in comparison with the concentrations used in that report, and decided the DSF concentrations to be used in eye drops. 19) In both in vitro and in vivo transcorneal penetration experiments using rabbit corneas only DDC was detected in the reservoir side or aqueous humor. We previously reported a sulfhydryl-rich protein, aldehyde dehydrogenase 3A1 (ALDH3A1), which is related to the conversion of DSF to DDC, and exists in abundance in the corneal stroma and endothelium. 19, 27, 28) Therefore, DSF in HPbCD solutions containing HPMC may be converted to DDC via catalysis by ALDH3A1 in the cornea. The amount of DDC penetration showed no significant difference between 0.1 and 0.25% DSF eye drops in the in vitro transcorneal penetration experiments (Fig. 1) . In contrast, in the in vivo transcorneal penetration experiments, the amount of DDC penetration was about 4-fold higher in the case of the 0.25% DSF eye drops than the 0.1% DSF eye drops, and the values of AUC DDC and k a were also higher for the 0.25% DSF eye drops than the 0.1% DSF eye drops (Fig. 2) . In the in vitro transcorneal penetration experiments, the viscosity and corneal contact area of the 0.1 and 0.25% DSF eye drops were almost the same, since the DSF eye drops were completely stirred in the chamber. These results suggest that the absorption rate for transcorneal DDC penetration is regulated by the viscosity and corneal contact area of the DSF eye drops. Therefore, we measured the viscosity the two DSF drop preparations. The viscosity of the 0.25% DSF eye drops was higher than that of the 0.1% DSF eye drops (1.85 mm 2 /s for the 0.1% DSF eye drops, 2.01 mm 2 /s for the 0.25% DSF eye drops; measured at 25°C by an Uberode type viscometer). It was known when the eye drops was lost from tear film within 30 s-2 min, while a small amount remained associated with conjuctival tissue. On the other hand, the increase in viscosity of the eye drops remained a higher storage on the surface of a cornea. 29) These suggest that the 0.25% DSF eye drops have a higher storage on the surface of a cornea, and this lead to the higher absorption rate for 0.25% DSF eye drops than the 0.1% DSF eye drops. In addition, free DSF and HPbCD-included DSF coexists both in 0.1 and 0.25% DSF solutions. Moreover, the concentrations of free DSF in those solutions are almost same. Therefore, the free DSF related strongly to the transcorneal penetration.
The intravenous administration of a 5% glucose solution is a simple and reproducible technique for the screening of anti-glaucoma agents. 24) In this study, the IOP in rabbits receiving a rapid infusion of 5% glucose solution initially rose, and returned to baseline levels by 50 min after infusion. This indicates that the IOP elevation in this experiment may provide a suitable model for acute glaucoma. The degree of IOP elevation in rabbits receiving a rapid infusion of 5% glucose solution was reduced by the instillation of DSF eye drops with both 0.1 and 0.25% DSF eye drops providing IOP-reducing effects sufficient to protect against glaucoma. In addition, the IOP-reducing effect was greater for the higher DSF concentration (Table 3 ). These results demonstrate that DSF eye drops containing 0.1 or 0.25% may be useful agents for the treatment of glaucoma. The rabbits rapid infused with 5% glucose solution were instilled with 50 ml of saline or 0.5% DSF eye drops. Saline instilled rabbit (᭺), 0.5% DSF eye drops instilled rabbit (᭹). The data are represent the meansϮS.E. of 5 independent rabbits. * pϽ0.05, vs. saline instilled rabbit. 
